FORT MYERS, Fla. — NeoGenomics, Inc., a provider of oncology diagnostic solutions focused on precision medicine, said Natera has voluntarily withdrawn its appeal in the ongoing RaDaR patent litigation, leaving intact a federal court ruling in NeoGenomics’ favor.
The company said Natera dismissed its appeal of the North Carolina District Court’s August 2025 decision, and NeoGenomics subsequently dismissed its cross-appeal. As a result, the ruling by the U.S. District Court for the Middle District of North Carolina will remain in place.
In that decision, the court granted NeoGenomics’ motion for summary judgment and ruled that the patent claims asserted by Natera were invalid because they claimed ineligible subject matter. The court dismissed Natera’s claims against NeoGenomics with prejudice and entered a declaratory judgment of invalidity covering both of Natera’s asserted patents.
NeoGenomics said the resolution of the appeal clears the way for the company to focus on its commercial plans, including a full U.S. clinical launch of its RaDaR ST molecular residual disease assay, which is targeted for the first quarter of 2026.
“We are very pleased that Natera has voluntarily decided to end this litigation process,” said Tony Zook, CEO of NeoGenomics. “While we were confident in our position, this latest development nonetheless allows us to focus our full attention on executing a robust clinical launch of RaDaR ST in the first quarter of next year.”
